not generalizable to other RCTs. Goal Attainment Scaling (GAS); Global Measures. Clinician Interview-Based Impression of Change plus caregiver input ( CIBIC. interview [CIBIC-plus]). The ADAS- cog, disease assessment in dementia scale, and neuropsychiatric inventory are recorded by supervising site investigator, but . The Clinician Interview-Based Impression of Change, plus carer interview (CIBIC -Plus), is widely used in antidementia drug trials. It comprises Likert scales for.
|Published (Last):||8 October 2010|
|PDF File Size:||2.82 Mb|
|ePub File Size:||5.65 Mb|
|Price:||Free* [*Free Regsitration Required]|
CIBIC-plus Publications | PubFacts
Dealing with a cohort that has different biological and medical demands requires pharmacists to pay particular attention to details when treating this subset of individuals. In this week, double-blind, multinational study NCToutpatients with AD Mini-Mental State Examination scores of were randomized to receive once-daily, mg, extended-release memantine or placebo.
We directly assessed the clinical trials’ evidence for memantine’s efficacy in mild Alzheimer disease AD. The aim of the present report was to examine the reliabilities of the subscale items and investigate their relationships with CGIC.
Current treatments for Alzheimer’s disease AD provide modest symptomatic relief but do not slow the progression of the disease. J Alzheimers Dis ;20 1: J Clin Psychopharmacol Aug;29 4: Kagawa University, Kita-gun, Kagawa, Vibic. Jpn J Geriatr Psychiatry.
First, the central raters watched the videotaped CIBIC interviews of patients and caregivers to assess the patients by subscales at baseline and after the follow-up period. Thus, for longer study duration, the assessment shows less reliability and objectivity. Read More View Article. Patients were randomized to donepezil 10 mg daily or placebo for 24 weeks.
The objective of this review was to consider available efficacy, tolerability, and safety data from studies of ChEIs in PDD.
CIBIC Plus-J Assessment Using a Videotaped Method in Alzheimer’s Disease Patients
A 6-month, open-label study of memantine in patients with frontotemporal dementia. Epub Jul 4.
J Am Geriatr Soc Jul 27;61 7: Previously published systematic review on cholinesterase inhibitors ChEIs in Alzheimer’s disease. Memantine treatment in patients with mild to moderate Alzheimer’s disease: Kagawa University, Miki, Japan. The CIBIC plus-J interviews were performed by clinicians, nurses, clinical psychologists, and psychiatric social workers who were familiar with dementia, as the central raters assessed CIBIC plus-J based on videotaping.
BMC Neurol Aug 30;7: Measurement of observer agreement. J Psychopharmacol Sep 28;22 7: The interviewers interviewed patients and caregivers twice, once at baseline and once after a follow-up period of 1—24 weeks. The LCPUFA docosahexaenoic acid and arachidonic acid are important components of neuronal membranes, while eicosapentaenoic acid, docosahexaenoic acid, and arachidonic acid also affect cardiovascular health and inflammation. Several randomized, placebo-controlled trials have sought to evaluate the effect of latrepirdine on cognition, function and behaviour in patients with AD.
Search Our Scientific Publications & Authors
Prospectively defined analyses failed to demonstrate a statistically significant benefit of memantine treatment compared with placebo on the Severe Impairment Battery SIB at week 24 end point, although a significant advantage was observed for memantine at weeks 12 and Epub May Clinical diagnosis of Alzheimer’s disease: Efficacy was evaluated using measures of cognition, daily function, and behavior. The latter was similar to the kappa coefficient of 0.
Alzheimers Res Ther 18;7 1: A new rating scale for Alzheimer’s disease. Statistical Methods for Research Workers. Donepezil is an established treatment for mild, moderate, and severe Alzheimer’s disease AD. Trials 06 8;17 1: Memantine has been approved by the Food and Drug Administration for the treatment of moderate-to-severe Alzheimer’s disease AD.
Two galantamine titration regimens in patients switched from donepezil. To evaluate the additional benefit of combination therapy over monotherapy with either AChEI or memantine.
Latrepirdine for Alzheimer’s disease.
The clinical trial registration number is UMIN Here, we present the method and results. To evaluate the efficacy and safety of donepezil for severe Alzheimer disease AD. This study examined the efficacy and safety of memantine monotherapy in patients with moderate-to-severe Alzheimer disease AD. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. ICC in the present study was 0.
We examined how this change compared with measures of clinical meaningfulness. This study allowed CIBIC plus-J interview by primary physicians, ADAS raters of the patients, or under unavoidable circumstances different interviewers between baseline and follow-up period. Epub Jul 7. Simple kappa was 0.
A questionnaire survey of family caregivers caring for dementia patients at home was carried out to investigate how the use of these services might affect the information about the patients provided by the caregivers.
Okamoto, Department of Clinical Development, and the following statisticians who were involved in the statistical analysis: